Evidence map›Paper›PMID 28176139›Full record

ArticleCancer causes & control : CCC2017

Lower prostate cancer risk in Swedish men with the androgen receptor E213 A-allele.

Magdalena Bentmar Holgersson, Yasir Ruhayel, Magnus Karlsson, Aleksander Giwercman, Anders Bjartell, Claes Ohlsson, Dan Mellström, Östen Ljunggren, Mohammad-Ali Haghsheno, Jan-Erik Damber and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer causes & control : CCC, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Magdalena Bentmar HolgerssonDepartment of Translational Medicine, Lund University, Jan Waldenströms gata 35, Building 91, Plan 10, 205 02, Malmö, Sweden. Magdalena.Bentmar_Holgersson@med.lu.se.
Yasir RuhayelDepartment of Urology, Skåne University Hospital, Malmö, Sweden.
Magnus KarlssonDepartment of Orthopedics and Clinical Sciences, Lund University, Malmö, Sweden.
Aleksander GiwercmanDepartment of Translational Medicine, Lund University, Jan Waldenströms gata 35, Building 91, Plan 10, 205 02, Malmö, Sweden.
Anders BjartellDepartment of Translational Medicine, Lund University, Jan Waldenströms gata 35, Building 91, Plan 10, 205 02, Malmö, Sweden.
Claes OhlssonDepartments of Internal Medicine and Clinical Nutrition and Geriatrics at the Sahlgrenska Academy, Center for Bone and Arthritis Research, Gothenburg University, Gothenburg, Sweden.
Dan MellströmDepartments of Internal Medicine and Clinical Nutrition and Geriatrics at the Sahlgrenska Academy, Center for Bone and Arthritis Research, Gothenburg University, Gothenburg, Sweden.
Östen LjunggrenDepartment of Medical Sciences, University of Uppsala, Uppsala, Sweden.
Mohammad-Ali HaghshenoDepartment of Urology, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Jan-Erik DamberDepartment of Urology, Sahlgrenska Cancer Center, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Yvonne Lundberg GiwercmanDepartment of Translational Medicine, Lund University, Jan Waldenströms gata 35, Building 91, Plan 10, 205 02, Malmö, Sweden.
Lund University · SEUniversity of Gothenburg · SESkåne University Hospital · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn a previous population-based study on 3369 European men with self-reported prostate cancer (PCa), it was shown that androgen receptor (AR) haplotype designated H2 was associated with high levels of serum PSA (prostate-specific antigen) concentration, and, at the same time, with low risk for PCa. The aim of this study was to replicate this finding in other cohorts, with registry-based cancer diagnosis.

methodsUsing data from two population-based cohorts; the Malmö Diet and Cancer Study (MDCS, n = 12,121) and the Swedish Osteoporotic fractures in men study (MrOS, n = 1,120), 628 men with PCa and 1,374 controls were identified and genotyped. PCa data were collected from the Swedish national cancer registry. PCa odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for carriers of the particular AR haplotype, tagged by the rs6624304 T-allele.

resultsThe 15% of men who were carriers of the AR haplotype H2 had approximately one-third lower risk for PCa diagnosis compared to those with the most common H1 variant (OR 0.65; 95% CI 0.45-0.94; p = 0.021). The same trend, although not statistically significant (OR 0.75; 95% CI 0.47-1.24; p = 0.275), was observed in MrOS Sweden. When both cohorts were merged, an even more significant result was observed (OR 0.68; 95% CI 0.51-0.90; p = 0.008).

conclusionsSwedish men with the variant AR haplotype H2, tagged by rs6624304, have significantly lower risk of PCa compared to those with the more common variant.

Indexed as

AdultAgedAllelesHaplotypesHumansMaleMiddle AgedOdds RatioProstate-Specific AntigenProstatic NeoplasmsReceptors, AndrogenRisk FactorsSwedenProstate-Specific AntigenReceptors, AndrogenAndrogen receptorGenetic variantsProstate cancer

Identifiers

PMID28176139
PMCPMC5325831
OpenAlexW2587624424

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.